Latest news with #Guerbet
Yahoo
26-05-2025
- Business
- Yahoo
Guerbet : Changes in the composition of the Guerbet board of directors.
CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORS Reorganization of the Board of Directors Directors' terms of office reduced to 4 years Appointment of Ms Michèle Lesieur and Mr Eric Drapé as independent directors Reappointment of two directors _________________________________________________________________ Villepinte, May 23rd, 2025 Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, announces, following the Annual General Meeting of May 23, 2025: - The reorganization of its Board of Directors- The reduction of directors' terms of office to 4 years- The appointment of Michèle Lesieur and Eric Drapé as independent directors- Renewal of the terms of office of Céline Lamort and Marc Massiot. Recomposition of the Board of Directors Guerbet's Annual General Meeting today voted to reduce the terms of office of directors from six (6) years to four (4) years, in order to ensure compliance with the recommendations of the Afep-Medef Code of corporate governance for listed companies to which the Company refers. This change applies to all new directorships as well as to current terms of office, initially granted for a period of (6) six years. Consequently, the terms of office of Claire Jouault Massiot and Céline Lamort, as well as those of Mark Fouquet, Didier Izabel and Jean-Sebastien Raynaud, expired at the Annual General Meeting. It should also be noted that Ms. Pascale Auger resigned as a director of the Company to the Board of Directors on the date of the Annual General Meeting. At the Annual General Meeting, two directors were newly appointed, and two directors were re-elected, bringing the total number of directors to nine (compared with 12 previously). Appointment of Michèle Lesieur and Eric Drapé as independent directors The Annual General Meeting has appointed Michèle Lesieur as an independent director for a three-year term. Michèle Lesieur has extensive experience of managing companies in the healthcare sector, in both large groups and SMEs. She headed the Philips Group's international medical imaging business for several years before becoming President of Philips France from 2011 to 2016. In 2016, she became CEO of Supersonic Imagine, a listed medical imaging company, and organized its sale to the US group Hologic in 2019. Ms. Lesieur has also served as an independent director on the boards of EOS Imaging (2020-2021), Provepharm (2022-2023) and Intelligent Ultrasound (2021 to February 2025). She has been an independent director of Prodways Group since 2018 and of Intrasense since 2020. She today resigned from her directorship of Intrasense. The Annual General Meeting appointed Mr Eric Drapé as an independent director for a four-year term. Until 2024, Eric Drapé was Executive Vice President, Global Operations and a member of the Executive Committee of Teva Pharmaceuticals. In this capacity, he oversaw operations at over 50 sites, as well as Supply Chain, Quality and CSR, Purchasing, Engineering and Industrial Development activities worldwide. For over 35 years, Mr Drapé held a number of senior positions in the pharmaceutical industry, covering global operations and quality at Teva Pharmaceuticals, Ipsen Pharma and Novo Nordisk. He brings a wealth of international experience, having held positions in Denmark, France, Israel and the USA. Mr. Drapé has also been a director of LFB since 2018. Reappointment of Ms Céline Lamort and Mr Marc Massiot as Directors Guerbet's Annual General Meeting also reappointed two Directors : - Ms. Céline Lamort, member of the Board of Directors since 2015, Director representing the majority shareholder, for a two-year term;- Marc Massiot, member of the Board of Directors since 2021, Director representing the majority shareholder, for a four-year term; Guerbet's Board of Directors now comprises nine members: Hugues Lecat, Chairman of the Board, independent Director* Carine Dagommer, DirectorEric Drapé, Independent Director* Marie de la Simone, Employee DirectorEric Guerbet, DirectorCéline Lamort, DirectorMichèle Lesieur, Independent Director* Nicolas Louvet, DirectorMarc Massiot, Director The Board of Directors would like to express its sincere thanks to Pascale Auger, Claire Jouault Massiot, Marc Fouquet, Didier Izabel and Jean-Sébastien Raynaud for their contribution to the Board's work. He also warmly welcomes Mrs Michèle Lesieur and Mr Eric Drapé, and looks forward to their future collaboration. *These 3 directors can be qualified as independent members under the criteria of the Afep-Medef Code. About Guerbet At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 99 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our sales to research and development in four centres in France and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €841 million in revenue in more information, visit: Contact : Christine Allard – Senior VP Public affairs and communicationsEmail: +33 6 30 11 57 82 Attachment PRESS RELEASE BOARDS OF DIRECTORS 2025_ENGSign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Guerbet : Changes in the composition of the Guerbet board of directors.
CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORS Reorganization of the Board of Directors Directors' terms of office reduced to 4 years Appointment of Ms Michèle Lesieur and Mr Eric Drapé as independent directors Reappointment of two directors _________________________________________________________________ Villepinte, May 23rd, 2025 Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, announces, following the Annual General Meeting of May 23, 2025: - The reorganization of its Board of Directors- The reduction of directors' terms of office to 4 years- The appointment of Michèle Lesieur and Eric Drapé as independent directors- Renewal of the terms of office of Céline Lamort and Marc Massiot. Recomposition of the Board of Directors Guerbet's Annual General Meeting today voted to reduce the terms of office of directors from six (6) years to four (4) years, in order to ensure compliance with the recommendations of the Afep-Medef Code of corporate governance for listed companies to which the Company refers. This change applies to all new directorships as well as to current terms of office, initially granted for a period of (6) six years. Consequently, the terms of office of Claire Jouault Massiot and Céline Lamort, as well as those of Mark Fouquet, Didier Izabel and Jean-Sebastien Raynaud, expired at the Annual General Meeting. It should also be noted that Ms. Pascale Auger resigned as a director of the Company to the Board of Directors on the date of the Annual General Meeting. At the Annual General Meeting, two directors were newly appointed, and two directors were re-elected, bringing the total number of directors to nine (compared with 12 previously). Appointment of Michèle Lesieur and Eric Drapé as independent directors The Annual General Meeting has appointed Michèle Lesieur as an independent director for a three-year term. Michèle Lesieur has extensive experience of managing companies in the healthcare sector, in both large groups and SMEs. She headed the Philips Group's international medical imaging business for several years before becoming President of Philips France from 2011 to 2016. In 2016, she became CEO of Supersonic Imagine, a listed medical imaging company, and organized its sale to the US group Hologic in 2019. Ms. Lesieur has also served as an independent director on the boards of EOS Imaging (2020-2021), Provepharm (2022-2023) and Intelligent Ultrasound (2021 to February 2025). She has been an independent director of Prodways Group since 2018 and of Intrasense since 2020. She today resigned from her directorship of Intrasense. The Annual General Meeting appointed Mr Eric Drapé as an independent director for a four-year term. Until 2024, Eric Drapé was Executive Vice President, Global Operations and a member of the Executive Committee of Teva Pharmaceuticals. In this capacity, he oversaw operations at over 50 sites, as well as Supply Chain, Quality and CSR, Purchasing, Engineering and Industrial Development activities worldwide. For over 35 years, Mr Drapé held a number of senior positions in the pharmaceutical industry, covering global operations and quality at Teva Pharmaceuticals, Ipsen Pharma and Novo Nordisk. He brings a wealth of international experience, having held positions in Denmark, France, Israel and the USA. Mr. Drapé has also been a director of LFB since 2018. Reappointment of Ms Céline Lamort and Mr Marc Massiot as Directors Guerbet's Annual General Meeting also reappointed two Directors : - Ms. Céline Lamort, member of the Board of Directors since 2015, Director representing the majority shareholder, for a two-year term;- Marc Massiot, member of the Board of Directors since 2021, Director representing the majority shareholder, for a four-year term; Guerbet's Board of Directors now comprises nine members: Hugues Lecat, Chairman of the Board, independent Director* Carine Dagommer, DirectorEric Drapé, Independent Director* Marie de la Simone, Employee DirectorEric Guerbet, DirectorCéline Lamort, DirectorMichèle Lesieur, Independent Director* Nicolas Louvet, DirectorMarc Massiot, Director The Board of Directors would like to express its sincere thanks to Pascale Auger, Claire Jouault Massiot, Marc Fouquet, Didier Izabel and Jean-Sébastien Raynaud for their contribution to the Board's work. He also warmly welcomes Mrs Michèle Lesieur and Mr Eric Drapé, and looks forward to their future collaboration. *These 3 directors can be qualified as independent members under the criteria of the Afep-Medef Code. About Guerbet At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 99 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our sales to research and development in four centres in France and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €841 million in revenue in more information, visit: Contact : Christine Allard – Senior VP Public affairs and communicationsEmail: +33 6 30 11 57 82 Attachment PRESS RELEASE BOARDS OF DIRECTORS 2025_ENG
Yahoo
26-03-2025
- Business
- Yahoo
GUERBET : 2024 full-year results.
2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER)1 and on a like-for-like basis2 Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA excluding France (+8.8%) Solid increase in profitability Restated EBITDA margin3 of 14.9%, versus 13.1% a year earlier Operating income up 28.2% to €49.6 million 2025 targets Further growth in profitability: restated EBITDA margin expected above 15%, backed by revenue growth of 3-5% at CER and like-for-like Free cash flow in positive territory Villepinte, March 26, 2025, 5:45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated financial statements for fiscal year 2024. Full-year revenue came to €841.1 million, up 7.1% compared with 2023. Excluding the currency effect (-€12.3 million), mainly related to the Brazilian real and the Japanese yen, Group sales at constant exchange rates (CER)1 rose by 8.6%. At constant exchange rates and on a like-for-like basis2, Guerbet saw growth of 9.0% in 2024, an acceleration in performance compared with 2023 (+5.9%). In EMEA, revenue increased by 1.1% at CER and like-for-like. Excluding France, where activity fell (-11.8%) following the reform of the supply chain for contrast agents, growth in EMEA was 8.8%. In the Americas, sales at CER and like-for-like grew by 20.5%, reflecting an exceptional performance in the first half (+29.1% at CER) linked to the catch-up of lost X-ray sales in 2023, and continued strong momentum in the second half (+13.3%), driven in particular by Latin America. In Asia, growth reached 10.1% at CER and like-for-like, marking another dynamic year despite the decline in activity in South Korea, affected by a major physician strike. By business, revenue in Diagnostic Imaging increased by 9.0% at CER and like-for-like, attributable to: In the X-ray division (+12.6%), volumes and prices remaining very positive, both for Xenetix® and Optiray®. In the IRM division (+3.0%), momentum in the Dotarem® / EluciremTM franchise slowing as a result of the situation in France: full-year growth of the division was 9.4% excluding the impact of France. Having reached the unprecedented €100 million mark in fiscal 2024, sales in Interventional Imaging rose by 8.8% at CER and like-for-like, driven all the while by the solid performance of Lipiodol®, particularly in vascular embolization. In millions of eurosConsolidated financial statements (IFRS) 2023Published 2024Published Revenue 785.7 841.1 EBITDA* 98.8 119.4 % of revenue 12.6% 14.2% Operating income/(expense) 38.7 49.6 % of revenue 4.9% 5.9% Net income/(loss) 22.2 13.5 % of revenue 2.8% 1.6% Net debt 335.8 344.9 * EBITDA = Operating income + net depreciation, amortization and provisions. Solid improvement in operating profitability In 2024, the Group generated an EBITDA margin of 14.2% of revenue. After restatement for non-recurring costs related to the optimization of the operating framework and changes in the sales model, the margin rate came to 14.9%, perfectly in line with the initial target (>14.4%), versus 13.1% a year earlier. This 1.8 point improvement was due to continued good financial discipline, the positive trend in sales prices, and the improvement in the product mix, which was driven in particular by the effects of the reform in France (gradual shift towards packaging in multi-use bottles). Guerbet's operating income came to €49.6 million in 2024, up 28.2% on the previous year. Net income was €13.5 million, compared with €22.2 million in 2023. As expected by the Group, it includes a sharp increase in interest expenses linked to the rise in interest rates; financial expenses amounted to €22.3 million for the year, compared with €8.6 million in 2023. In addition, Guerbet recorded a foreign exchange loss of €5.7 million in 2024. A sharp improvement in free cash flow compared to 2023 On the balance sheet, shareholders' equity increased to €394 million at December 31, 2024 compared with €378 million a year earlier. Net debt amounted to €345 million, showing financial leverage (net debt/EBITDA) of 2.9. This ratio is significantly better than the 2023 level of 3.4. Free cash flow (FCF) came out slightly negative at -€9.1 million, mainly due to late payments in France related to the new distribution channel (increased weight of the public sector). Nonetheless, FCF shows a significant improvement in 2024 compared with the 2023 level (-€65.4 million). To support long-term development of Guerbet, the Board of Directors will propose to the Annual General Meeting of May 23, 2025, that no dividends be paid to shareholders related to fiscal year 2024. Outlook for 2025: strengthen its three strategic pillars Guerbet intends to continue rolling out an ambitious sales strategy in 2025 backed by an unrivaled portfolio of contrast agents. The following priorities have been defined for each of the three strategic pillars for the current fiscal year: Diagnostic Imaging: 1) strengthen the profitability of the X-ray division by activating several levers (promote multi-use, automate industrial processes); 2) continue to gain market share in MRI through the unique duo Dotarem® / EluciremTM, the latter of which will benefit in 2025 from its expansion in the United States, its first full year in Germany, the United Kingdom and France, and its launch in Switzerland on 1 March; Interventional Imaging: pursue growth in Lipiodol® by accelerating its expansion into vascular embolization, while intensifying R&D in new applications, including Lipiojoint which was recently designated by the US Food and Drug Administration (FDA) as a 'Breakthrough Device' for the treatment of osteoarthritis of the knee; Artificial Intelligence: develop sales of Guerbet solutions, having obtained the CE logo in late 2024 and early 2025 for the new version of the prostate cancer algorithm, for DUOncoTM Liver (liver lesions) and DUOncoTM Bone (bone lesions), while the pancreas solution was recently named as a 'Breakthrough Device' by the US Food and Drug Administration (FDA) for the early detection of pancreatic lesions. Financial targets: revenue growth of 3-5% at CER and like-for-like and restated EBITDA margin above 15% in 2025 Having achieved strong growth in its activity and a solid improvement in its profitability in 2024, Guerbet will continue to benefit in 2025 from a structurally growing demand for contrast agents. The Group's trajectory should therefore remain positive despite the situation in France, where the reform of the supply chain and the reimbursement system will continue to generate disruptions before they are expected to stabilize completely in 2026. The Group believes this reform will ultimately have lasting and contrasting effects on its subsidiary in France, with a negative impact on sales but a positive impact on the product mix and the margin rate. In terms of operating profitability, the Group expects to see further growth in 2025 fueled by cost control and changes in its product mix, while price increases are expected to slow (end of the pass-through effect of iodine prices). Finally, Guerbet expects investments to remain stable and an improvement in its WCR, benefiting cash generation. Against this backdrop, it expects revenue growth of 3-5% at constant exchange rates and like-for-like in 2025. This forecast includes an acceleration in the second half of the fiscal year after a first quarter decline of around 10% and a first half expected to be stable at best, due to an exceptionally high first half of 2024 and an ongoing effect from the situation in France. Full-year restated EBITDA margin is expected above 15%. Free cash flow is expected to be positive in 2025. Next event: Publication of 2025 1st quarter revenue24 April 2025 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 98 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €841 million in revenue in 2024. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group's actual performance and results and those presented explicitly or implicitly by these forward-looking forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group's control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group's activities can be found in Chapter 4.9 'Risk factors' of the Group's Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group's website ( Glossary Net debt: Net financial debt is defined as the sum of current and non-current borrowings less cash and cash equivalents and marketable securities. EBITDA: EBITDA is defined as operating income plus net depreciation, amortization, impairment and provisions for risks. Restated EBITDA: Restated EBITDA is defined as EBITDA minus non-recurring expenses paid to employees following their departure due to restructuring. Free cash flow (FCF): Free cash flow is defined as the change in net debt from one year to the next. Like-for-like basis: Like-for-like basis refers to the scope excluding the urology and Accurate businesses, sold in July 2024 and January 2025 respectively. At constant exchange rates: At constant exchange rates means the impact of exchange rates is eliminated by recalculating sales for the period based on the exchange rates used for the previous year. 1 At constant exchange rates: the impact of exchange rates was eliminated by recalculating sales for the period based on the exchange rates used for the previous financial year.2 Excluding the urology and Accurate businesses, sold in July 2024 and January 2025 respectively.3 Excluding non-recurring costs related to the optimization of the operational framework and changes to the sales model. Contacts: Guerbet Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / Allard, Head of Communications +33 6 30 11 57 82 / Seitosei Actifin Marianne Py, Financial Communications +33 1 80 48 25 31 / Jennifer Jullia, Press +33.1.56.88.11.19 / Attachment 25 0326 CP GBT RA VENG Def 03Sign in to access your portfolio
Yahoo
18-03-2025
- Business
- Yahoo
DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions on CT scan.
DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions onCT scan The first CE-marked IA for the detection of bones lesions A world premier : an innovate solution expected of the entire medical profession Enhancement of DUOncoTM, IA range for integration into medical imaging systems Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans. On this occasion, Alexandre Salvador, Intrasense's CEO, says : "This CE marking is a key milestone that validates Intrasense and Guerbet's expertise in developing AI solutions for reference medical imaging in oncology. Together, we are developing and bringing to market ever more effective solutions tailored to the needs of the field. DUOnco™ Bone strengthens our product portfolio by offering radiologists an accurate and effective tool for detecting bone lesions. Its flexibility as a stand-alone solution also enables us to enrich the offerings of our partners, whether PACS vendors or marketplace platforms, by bringing differentiating added value." A major impact for oncology imaging Early detection of bone lesions is a major clinical challenge in oncology, as these lesions are frequently under-detected due to the large volume of images to be analyzed and the complexity of bone structures. Despite technological advances in medical imaging, studies show that up to 30% of bone metastases are not detected on CT scans1, making bone one of the most frequent sites of diagnostic errors in CT imaging2. DUOnco™ Bone, co-developed by Intrasense and Guerbet, is the first CE-marked AI solution for detecting bone lesions on CT scan images. Designed to automatically analyze TAP (thorax-abdomen-pelvis) scanner images and detect bone lesions, the solution relies on cutting-edge deep learning algorithms to accurately identify suspicious anomalies and provide their 3D coordinates to clinicians. DUOnco™ Bone optimizes radiologists' workflow by and speeds up the interpretation of results. This technological advance enables faster and safer patient management, particularly by facilitating early detection of bone lesions. With DUOnco™ Bone, healthcare establishments benefit from cutting-edge diagnostic assistance technology, improving the productivity of radiologists, the reliability of analyses and the quality of care provided to patients. From a strategic standpoint, this breakthrough reinforces Intrasense and Guerbet's positioning as major players in AI for medical imaging, paving the way for new partnership opportunities and international deployments Enhancement of the DUOnco™ high medical value AI range DUOnco™ solutions integrate seamlessly into existing workflows, without changing user habits. Designed for maximum flexibility, the DUOnco™ range is also available as a stand-alone solution: its high medical value artificial intelligence algorithms in oncology can be integrated into third-party solutions, adapting to the needs of healthcare facilities and software publishers. Compatible with PACS systems, third-party viewers, marketplaces and other medical imaging infrastructures, DUOnco™ facilitates deployment, without technical constraints or disruption to clinical workflows, for rapid adoption and seamless integration into existing environments. Liflow®: native integration for optimized management At the same time, the DUOnco™ range integrates natively with Liflow®, Intrasense's oncology imaging platform. This integration guarantees seamless examination management and optimal centralization of results in a unified environment, accessible from a single tool. The addition of DUOnco™ Bone to the Liflow®3 ecosystem represents a major strategic advance, strengthening Intrasense's offering and optimizing the diagnosis of bone lesions. This innovation marks a key step towards ever more efficient and integrated AI, supporting radiologists in their day-to-day work. Other solutions, notably in the field of pancreatic imaging, will soon complete this package to offer even broader clinical coverage. Prof. Nathalie Lassau, Professor of Radiology at the University of Paris-Saclay and radiologist at Gustave Roussy, states: "In our practice, the evaluation of bone metastases is a critical step that requires great precision due to the complexity of the examinations. DUOnco™ Bone, integrated with Liflow®, will provide invaluable support by optimizing our analysis of TAP scanner images and facilitating our decision-making With this intelligent assistance, we have a tool that will improve our efficiency to contribute directly to the optimization of the oncology care pathway." About Intrasense A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries to facilitate and secure diagnosis, decision-making and therapeutic an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new multidisciplinary and collaborative platform dedicated to oncology, to optimize patient care and follow-up. A digital subsidiary of the Guerbet Group since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save information on About Guerbet Guerbet is a world leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices and AI-based solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual sales in research and development, with dedicated innovation centers in France and the United States. The company (GBT) is listed on Euronext Paris and has reported sales of 841 million euros in further information: Contacts INTRASENSEChargée des communicationsSalomé SylvestrePhone: +334 67 13 01 30investisseurs@ Communications ManagerMatthieu BruneauPhone: +336 78 83 89 96 Analystes & InvestisseursFoucauld CharavayPhone: +336 37 83 33 19intrasense@ PresseIsabelle Dray Phone: +331 56 88 11 1 Ha JY, Jeon KN, Bae K, Choi BH. Effect of Bone Reading CT software on radiologist performance in detecting bone metastases from breast cancer. Br J Radiol 2017; 90: 201608092 Kasalak Ö et al. Work overload and diagnostic errors in radiology. European Journal of Radiology 2023, Volume 167, 1110323 Available in the upcoming Liflow® 3.0 release Attachment PR_Duonco-bone_EN
Yahoo
06-02-2025
- Business
- Yahoo
GUERBET : 2024 revenue.
2024 revenue Solid growth momentum for the second year in a row Full-year revenue: €841.1 million, with growth of 9.0% on a like-for-like basis and at CER This performance was achieved thanks to strong momentum in the Americas (+20.5%) and Asia (+10.1%) and despite the contraction of activity in France Details on the 2024 financial statements Expected Restated EBITDA margin close to 14.9% Free cash flow expected to be slightly negative Significant improvement in financial leverage (net debt/EBITDA) Villepinte, February 6, 2025, 5:45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is publishing its full-year revenue. At 31 December 2024, the Group's sales totalled €841.1 million, up 7.1% compared with 2023. This change includes an unfavourable currency effect of €12.3 million, mainly due to South American and Asian currencies. At constant exchange rates (CER1), business grew by 8.6% in 2024. At constant exchange rates and on a like-for-like basis, i.e. excluding the urology and Accurate businesses which were sold in July 2024 and January 2025 respectively, growth reached 9.0%. This performance is very close to the annual guidance communicated during the half-year results. It follows another year of remarkable growth of 6.4% at CER in 2023. Breakdown of consolidated Group revenue (IFRS) by quarter In € millions 2023 20242024at CER1Q1 180.6 194.3 +7.6% 196.5Q2 198.0 224.9 +13.6% 226.8Q3 195.2 201.3 +3.1% 205.8Q4 211.8 220.6 +4.1% 224.3Total 785.7 853.4 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year. Geographical breakdown of consolidated Group revenue (IFRS) In millions of euros,at 31 December 2024 2023 2024 % change 2024at CER1 % changeat CER Sales in EMEA 347.7 352.4 +1.4% 351.6 +1.1% Sales in the Americas 217.6 255.5 +17.4% 262.1 +20.5% Sales in Asia 213.9 229.0 +7.0% 235.4 +10.1% Total like-for-like 779.2 836.9 +7.4%+9.0% Divested businesses (Accurate and urology) 6.5 4.2 - 4.2 - Total 785.7 841.1 +7.1% 853.4 +8.6% Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year. In EMEA, the Group made full-year revenue of €352.4 million, up 1.1% at constant exchange rates and on a like-for-like basis. 2024 saw a contraction in activity in France (-11.8%) following the implementation on 1 March 2024 of a new supply management system between distributors and practitioners. For the record, this contraction was nevertheless accompanied by an improvement in the product mix, which limited the impact on the Group's profitability. Excluding France, growth in the EMEA region was 8.8% at CER. In the Americas, sales increased by 20.5% at CER and on a like-for-like basis in 2024, driven by higher prices and volumes as well as a remarkable performance in Latin America thanks to significant market share gains. In the Americas as a whole, after exceptional momentum linked to the catch-up at the Raleigh site over three consecutive quarters until mid-2024, Guerbet continued to post double-digit growth (+11.8% in the fourth quarter alone). In Asia, the Group saw another very strong year, with annual growth of 10.1% at CER and on a like-for-like basis, driven in particular by China (+10.4%). This performance was achieved despite the decline in activity in South Korea, in connection with a major strike by doctors. In the fourth quarter of 2024, Guerbet generated growth in Asia of +9.3%. Breakdown of consolidated Group revenue (IFRS) by activity In millions of euros,at 31 December 2024 2023 2024 % change 2024at CER1 % changeat CER Diagnostic Imaging 686.3 737.1 +7.4% 748.1 +9.0% MRI 256.9 262.6 +2.2% 264.5 +3.0% X-ray 429.4 474.5 +10.5% 483.6 +12.6% Interventional Imaging 92.9 99.9 +7.5% 101.1 +8.8% Total like-for-like 779.2 836.9 +7.4% 849.2 +9.0% Divested businesses (Accurate and urology) 6.5 4.2 - 4.2 - Total 785.7 841.1 +7.1% 853.4 +8.6% Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year. By activity, sales at CER and on a like-for-like basis in Diagnostic Imaging amounted to €748.1 million at 31 December 2024, up 9.0% (+7.5% in the fourth quarter). In the IRM division, revenue grew by 3.0% year-on-year at CER and on a like-for-like basis. Growth in this division was hampered by the situation in France, which penalised sales of Dotarem® in particular. At the same time, there was a continued ramp-up of EluciremTM sales despite the delay in some markets, particularly in Switzerland where the commercial launch had to be postponed due to a regulatory delay. Excluding the France effect, growth in the IRM division was 9.4%. The X-ray division posted full-year growth of 12.6% at CER and on a like-for-like basis, driven by a sustained increase in volumes and prices for both Xenetix® and Optiray®. Over the year, Guerbet's performance in this activity was driven by both gains in market share and a favourable change in the product mix. In Interventional Imaging, the Group reached a new sales milestone of €100 million in 2024, with revenue at CER and on a like-for-like basis of €101.1 million. This represented growth of 8.8% over the year (+0.3% in the fourth quarter alone) thanks to the increase in prices and volumes for Lipiodol®, which saw particularly strong growth in vascular embolization. 2024 financial statements: confirmation of expected increase in profitability target Slightly negative expected free cash flow and significant improvement in financial leverage The solid growth generated by Guerbet in 2024, despite unprecedented disruptions in the French market, was accompanied by an overall improvement in its product mix and good cost control. The Group therefore is quietly confident it will achieve its profitability target for the 2024 financial year and has even raised this target: the restated EBITDA margin is expected to be close to 14.9%. At the same time, Guerbet now expects a slightly negative free cash flow level in 2024, due to late payments in France in connection with the new distribution channel. However, a significant improvement in the net debt/EBITDA ratio is expected for the 2024 financial year. The Group will take the opportunity during the publication of its full-year results, scheduled for 26 March, to specify its financial objectives for the current financial year. Next event: Publication of 2024 annual results26 March 2025 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group's actual performance and results and those presented explicitly or implicitly by these forward-looking forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group's control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group's activities can be found in Chapter 4.9 'Risk factors' of the Group's Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group's website ( Guerbet Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / Allard, Head of Communications +33 6 30 11 57 82 / Seitosei Actifin Marianne Py, Financial Communications +33 1 80 48 25 31 / Jennifer Jullia, Press +33.1.56.88.11.19 / Attachment 25 0206 CP GBT CA annuel V Final En
